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Abstract
Despite technical advances the last decade, patients with HPV/p16 negative head and neck cancer (being smokers and having affected 
performance and co-morbidities), still have a poor outcome after treatment. Hyperfractionated radiotherapy with concurrent cisplatin 
might be a reasonable way to pursue for improving their outcome. This strategy requires that adequate supportive care is available.
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The term hyperfractionated radiotherapy (HFR) is used when radiotherapy 
is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for 
doing so can be found in the differences in intrinsic radiosensitivity 
between tumours and late responding normal tissues. A small dose 
per fraction will tend to increase the therapeutic ratio between tumour 
and critical normal tissue and therefore allow a higher tumour dose 
to be given at the same level of normal tissue damage.1 This principle 
has been extensively explored for squamous cell carcinomas arising in 
the head and neck region. The impact of HFR was first demonstrated 
by Jean-Claude Horiot and colleagues2 in the (European Organisation 
for Research and Treatment of Cancer) EORTC 22791 trial, randomising 
356 patients with T2-T3, N0-N1, M0 oropharyngeal squamous cell 
carcinomas demonstrating a significant positive effect in tumour control 
without increased late normal tissue morbidity. Other studies followed3,4 
and meta-analyses have clearly demonstrated that HFR provides not 
just better tumour control but also significantly improved overall survival 
compared to conventional fractionation.5
The approach of combining radiation with concurrent chemotherapy 
have shown benefit in terms of better loco-regional control and overall 
survival both for conventional and accelerated radiotherapy.6 Likewise, 
HFR was tested against concurrent chemo-HFR often with platinum-
based regimes and although not that substantial evidence, data still 
demonstrate that chemo-HFR yield better results than HFR alone in 
terms of loco-regional control and overall survival7 and with similar 
frequency of severe late side-effects.8 
Despite this evidence, HFR has never gained a prominent place as 
standard treatment in the western world and the question is if this is 
due to not being considered evidence-based or due to more logistic 
challenges. At some point, the radiobiological approach to improving 
the results of radiotherapy have been overshadowed by technical 
advances such as intensity modulated radiotherapy (IMRT) and related 
techniques. For sure it seems that IMRT has spared normal tissue 
morbidity by spreading out dose over a larger volume, but we still 
have not demonstrated a better tumour control and survival.9 HFR is 
therefore still a valid candidate for increasing the total dose to the 
target in a safe way. On top of that, it is reasonable to believe that 
acute and late morbidity to HFR is easier to account for using modern 
radiotherapy techniques compared to 2-D techniques used in most of 
the large randomised trials on HFR.
Some of the arguments for not introducing HFR as a standard treatment are 
the costs, the uncertainties of the influence of human papillomavirus (HPV), 
hypoxia, patient compliance, high age of the patients and co-morbidity.  
Indeed, the question of resources is valid in large parts of the world, 
but in high-income countries the resources for delivering radiotherapy 
have increasingly been improved over the last 10 years10 and in most 
parts of Europe such a treatment could be feasible.
The large randomised trials were done in a time before the prognostic 
and predictive importance of HPV/p16 for radiotherapy was known. 
One could argue that the positive effect of HFR is difficult to interpret 
today where HPV/p16 positive tumours are very frequent and the 
distribution in these older studies are not known. However, HPV/p16 
positive tumours have been shown only to carry significant prognostic 
information within the oropharyngeal region11 and most studies of 
HFR have only included oropharyngeal tumours or have a balanced 
distribution of sites between the study arms. These facts, make it 
difficult to believe that there is a potential imbalance of patients with 
radiosensitive HPV/p16 positive tumours between study arms. Also, 
the studies were performed in a time where the absolute majority 
of patients were smokers and therefore had a mixed aetiology 
compared to being only HPV/p16 positive12 and consequently less 
positive outcome.13 
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Nevertheless, as the HPV/p16 positive tumours generally are very 
radiosensitive and the prognosis is very good, the focus for HFR should 
rather be the HPV/p16 negative patient that are also characterised by 
smoking, co-morbidity and a higher median age compared to the HPV/
p16 positive patients. As a consequence, there are often concerns for the 
patient’s compliance for such an intensive treatment. A recent Danish 
phase I-II study, Danish Head and Neck Cancer Group (DAHANCA) 28a, 
investigated HFR with concurrent low-dose weekly cisplatin and the 
hypoxic radiosensitizer in the HPV-negative, smoking population with 
locally advanced squamous cell carcinomas of the head and neck.14 
Co-morbidities and performance were registered and patients were 
allocated to different treatment groups based on increasing number of 
co-morbidities and decreasing performance. Data will be presented for 
the first time later this year, but it is already now known that treatment 
compliance – in spite of the criteria of the patient population – was fully 
in line with what can be expected from HPV/p16 positive non-smoking 
patients. In the end, one important parameter is to have the right set-
up for supportive care: proper access to tube-feeding, dieticians, social 
workers, housing close to the hospital, access to proper supportive 
medication, etc.
Despite all the technological advances throughout the last two 
decades there are still a need to optimise the treatment for this group 
of head and neck cancer patients with the poorest outcome. On top of 
all technical advances in the field, new focus on HFR is the reasonable 
radiobiological approach to take. n
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